| Literature DB >> 35455462 |
Efigenia Montalvo-González1, Zuamí Villagrán2, Sughey González-Torres2, Laura Elena Iñiguez-Muñoz3, Mario Alberto Isiordia-Espinoza4, José Martín Ruvalcaba-Gómez5, Ramón Ignacio Arteaga-Garibay5, José Luis Acosta6, Napoleón González-Silva7, Luis Miguel Anaya-Esparza7.
Abstract
Hibiscus sabdariffa Linn. Malvaceae (HS) is characterized by its edible calyxes. The HS calyxes are widely used for cosmetic, food, and medicinal applications. According to ethnobotanical evidence, decoction, infusion, or maceration extracts from HS calyxes have been used in folk medicine to treat many ailments. Moreover, several in vitro and in vivo studies have demonstrated the pharmacological properties and potential human health benefits of HS consumption. On the other hand, the evaluation of the physiological effects and health benefits of HS in clinical studies is most challenging. Therefore, this narrative review summarizes and discusses the physiological effects and health benefits of HS calyxes reported in clinical trials. Preparations obtained from HS calyxes (extracts, infusions, decoction, teas, beverages, capsules, and pills) are used as non-pharmacological therapies to prevent/control diverse chronic non-communicable diseases. The most-reported HS health benefits are its antihypertensive, antidyslipidemic, hypoglycemic, body fat mass reduction, nephroprotective, antianemic, antioxidant, anti-inflammatory, and anti-xerostomic activities; these effects are associated with the phytochemicals found in HS. Moreover, no adverse effects were reported during the clinical trials. However, clinical studies exhibited some limitations; thus, further studies are required to validate the clinical efficacy of HS in large-scale studies with higher doses and a good experimental design.Entities:
Keywords: Hibiscus sabdariffa; bioactive compounds; calyx; clinical trials; health benefits
Year: 2022 PMID: 35455462 PMCID: PMC9033014 DOI: 10.3390/ph15040464
Source DB: PubMed Journal: Pharmaceuticals (Basel) ISSN: 1424-8247
Figure 1Chemical structures of bioactive compounds identified in Hibiscus sabdariffa calyxes. Structures obtained from PubChem database, National Center for Biotechnology Information (gallic acid CID: 370, syringic acid CID: 689043, caffeic acid CID: 689043, chlorogenic acid CID: 1794427, hibiscus acid CID: 6481826, protocatechuic acid CID: 72, hydroxycitric acid CID: 123908, cyanidin-3-sambubioside CID: 3084569, delphinidin-3-sambubioside CID: 74977035, epigallocatechin gallate CID: 65064, quercetin CID: 5280343, kaempferol CID: 5280863, myricetin CID: 5281672).
Bioactive compounds identified in Hibiscus sabdariffa calyxes.
| Bioactive Compounds | Biological Activity | Reference |
|---|---|---|
| Cyanidin-3,5-diglucoside | Anti-inflammatory | [ |
| Cyanidine-3-sambubioside | Anti-inflammatory | [ |
| Delphinidin-3-sambubioside | Hepatoprotective | [ |
| Delphinidin-3-glucoside | Hepatoprotective | [ |
| 5-O-Caffeoyl-shikimic acid | Antimicrobial | [ |
| 3-Caffeoylquinic acid | Antioxidant | [ |
| 5-Caffeoylquinic acid | Anti-inflammatory | [ |
| 4-Caffeoylquinic acid | Antimicrobial | [ |
| 4- | Antihypertensive | [ |
| 3- | Antihypertensive | [ |
| Caffeic acid | Anti-inflammatory | [ |
| Chlorogenic acid | Immune booster | [ |
| Chlorogenic acid isomer I | Immune booster | [ |
| Chlorogenic acid isomer II | Immune booster | [ |
| Epigallocatechin gallate | Antihypertensive | [ |
| Gallic acid | Antihypertensive | [ |
| Hydroxycitric acid | Hypolipidemic | [ |
| Hibiscus acid | Vasorelaxant | [ |
| Kaempferol 3- | Anti-inflammatory | [ |
| Kaempferol 3-( | Hypolipidemic | [ |
| Myricetin 3-arabinogalactose | Hypolipidemic | [ |
| Antioxidant | [ | |
| Protocatechuic acid | Antimicrobial | [ |
| Quercetin | Antianxiety | [ |
| Quercitin-3-glucoside | Antianxiety | [ |
| Quercetin-3-rutinoside | Antidepressant | [ |
| Quercetin-3-sambubioside | Antianxiety | [ |
| Syringic acid | Antioxidant | [ |
Figure 2Biological activities of Hibiscus sabdariffa by in vitro, in vivo, or in silico tests.
Biological activities of Hibiscus sabdariffa calyxes by in vitro tests and animal models.
| Biological Activity | Type of Extract | Concentration/Dose | Model Assay | Main Results | Ref. |
|---|---|---|---|---|---|
| In vitro | |||||
| Antioxidant | Water-methanol-acetone | NI | DPPH• and ABTS+ | Extracts exhibited antioxidant properties | [ |
| Decoction and cold infusions | NI | Briggs–Rauscher | Beverages exhibited antioxidant properties | [ | |
| Antihypertensive | Anthocyanin-rich fraction | 84.5 µg/mL | ACE inhibitory assay | Fraction exhibited ACE inhibitory activity in a dose-dependent response | [ |
| Vasorelaxant | Hexane-ethyl acetate-methanol | 0.01 to 2 mg/mL | Rat aorta tissue | Fractions showed vasorelaxant effects by inhibition of Ca+ influx | [ |
| Antidiabetic | Aqueous | IC50 of 25.2 and 187 µg/mL, respectively | α-amylase and α-glucosidase inhibition assay | The extract exhibited higher α-amylase inhibitory activity than α-glucosidase | [ |
| Cardioprotective | Aqueous | 7 to 500 µg/mL | Doxorubicin-induced cytotoxicity in rat heart-derived myoblast H9c2 cardiac myocyte cells | The extract exhibited a protective effect on cardiomyocytes, increasing cell viability and decreasing cell apoptosis | [ |
| Antibacterial | Aqueous-methanolic | 20 mg/L | The extract exhibited potent antimicrobial activity against Gram-negative bacteria | [ | |
| Antiviral | Aqueous decoction | 100 mg/mL | Feline calicivirus, murine norovirus, and hepatitis A virus | Extracts showed antiviral activity to undetectable levels | [ |
| Antiproliferative | Methanolic | 0.2 to 1 mg/mL | Murine melanoma cell line (B16-F1) and human umbilical vein endothelial cells | Extract inhibits melanoma cell growth, migration, and tube formation in a dose-dependent response | [ |
| Cytotoxic | Aqueous | 0.05 to 0.5 mg/mL | Human breast cancer (MCF-7) cell line | The extract showed selective cytotoxic activity in a dose-dependent manner | [ |
| In vivo | |||||
| Neuroprotective | Aqueous decoction | 500 mg/kg bw for 24 days before BCCAO | Ischemic brain injury-induced adult male Wistar rats | The extract showed protective effects against neuronal damage induced by BCCAO | [ |
| Ethanolic | 200 to 500 mg/kg bw | Cypermethrin-induced oxidative stress in mice | The extract showed protective effects against toxicity induced by cypermethrin | [ | |
| Sedative | Maceration in hot water | 100 to 400 mg/kg bw | Apomorphine-induced stereotypic behavior test using Swiss albino mice | HSE significantly reduced the exploratory behavior in mice, similar to diazepam | [ |
| Antianxiety | Ethyl acetate fractions | 5 to 30 mg/kg bw | Elevated plus-maze rat model | HS fraction reduced anxiety at low concentrations | [ |
| Antidepressant | Ethyl acetate fractions | 5 to 30 mg/kg bw | Porsolt’s forced swim test in rats | HS fraction exhibited antidepressant properties at doses of 20 mg/kg | [ |
| Hepatoprotective | Aqueous extract | 100 to 200 mg/kg bw | Wistar rats injected with 2,4-dinitrophenylhydrazine (DNPH) | The extract inhibited the toxicity of DNPH in a dose-dependent response similar to the control drug | [ |
| Cardioprotective | Polyphenol-rich extract | 100 mg/kg bw | Hyperglycemia-induced cardiac oxidative stress rats | The extract ameliorated oxidative stress damage in diabetic heart | [ |
| Antihyperinsulinemic | Aqueous | 50 to 200 mg/kg bw | High fructose diet-induced insulin resistance rats | The extract showed a similar effect to metformin, an oral antidiabetic drug | [ |
| Antidiabetic | Aqueous | 30 mg/mL | Alloxan-induced diabetic rat | The extract showed hypoglycemic and antioxidant effects | [ |
| Anti-obesity | HS by-products | 10 g/100 g HF/HFr diet | HF/HFr-induced rats | HS by-products reduced adipocyte hypertrophy, insulin resistance, and hepatic steatosis | [ |
| Antihypertensive | Aqueous | 6 mg/mL bw | Salt hypertensive-induced rats | The extract attenuated the development of salt-induced hypertension | [ |
| Anti-inflammatory | Methanolic | 100 to 400 mg/kg bw | Paw edema-induced rat | The extract significantly reduced the paw size edema in a dose-dependent manner in less time than aspirin | [ |
| Hypolipidemic | Aqueous | 500 to 1000 mg/kg bw | Hypercholesterolemic rats | The extract exhibited hypolipidemic effects in a dose-dependent response | [ |
| Renal function improvement | Aqueous | 2 g/L | Metabolic syndrome-induced rats | The extract decreased oxidative stress and promoted normal renal function | [ |
| Anti-ulcer | Aqueous | 100 to 800 mg/kg bw | Indomethacin-induced gastric ulcer rats | The extract exhibited a protective effect against induced gastric ulcer | [ |
| Antianemic | Aqueous | 200 mg/kg bw | Healthy rats | The extract improved hematological parameters | [ |
NI: no information; BW: body weight; DPPH•: 2,2-diphenyl-1-picrylhydrazyl radical; ABTS+: 2,2′-Azinobis-(3-ethylbenzothiazoline-6-sulfonic acid); FRAP: ferric reducing antioxidant power; BCCAO: bilateral common carotid artery occlusion; HF/HFr: high-fat high fructose diet.
Figure 3Beneficial effects of Hibiscus sabdariffa in humans.
Effects of HS consumption on arterial blood pressure parameters.
| Country | Sex | Age (years) | Dose | Frequency/Days of Intervention | Sample Size | Design Study | Notes about Participants | Main Results | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | Exp. | CT | ||||||||
| Infusion/Decoction/Tea | |||||||||||
| Ghana | 1 | 0 | 33 | 2 bags | 1 day | 1 | O | HS was consumed 30 min before meals three times. | HS lowers blood pressure | [ | |
| Saudi Arabia | 0 | 16 | 25–35 | 2 g | 6 weeks | 16 | NI | Female participants | HS significantly decreased systolic and diastolic BP in addition to lowering the OxLDL levels of participants | [ | |
| Nigeria | NI | NI | 35–60 | 150 mg/Kg | 4 weeks | 25 | 25 | R | Moderate hypertension | Serum Na+ decreased significantly in the HS group | [ |
| Nigeria | NI | NI | 31–70 | 150 mg/Kg | 4 weeks | 25 | 25 | R | Participants with newly diagnosed, untreated mild to moderate hypertension | HS obtained greater therapeutic efficacy and duration of antihypertensive action without causing electrolyte imbalance | [ |
| Iran | 25 | 21 | 49.83 ± 3.38 | 1.25 g | 1 month | 23 | 23 | R, C | Subjects with stage 1 hypertension | HS significantly decreased systolic and diastolic blood pressure | [ |
| Iran | 8 | 45 | 55.37 ± 8.6 (HS) | 2 g | 1 month | 27 | 26 | R, C | Patients with diabetes and mild hypertension | Ingestion of HS significantly decreased systolic and diastolic BP compared to baseline | [ |
| Iran | NI | NI | 55.5 ± 10.1 | Two tablespoons/40 mL water | 15 days | 31 | 23 | R, C | Patients with moderated essential hypertension | Systolic and diastolic blood pressure decreased significantly when compared to the control group | [ |
| Mexico | NI | NI | 30–80 | 10 g | 4 weeks | 53 | 37 | R, C, DBT | Subjects with hypertension, without drug treatment | Both groups showed significant reductions in blood pressure, with no difference between them | [ |
| Indonesia | 0 | 30 | NI | 10 g | 2 days | 15 | 15 | Q | Postpartum mothers on antihypertensive drugs | Ingestion of HS showed significant effects on lowering systolic and diastolic blood pressure. | [ |
| Indonesia | NI | NI | 22–25 | 2 g | 7 days | 17 | 18 | Q | Subjects with hypertension | HS reduces blood pressure in pre/post-test measurements and is also compared to the control group | [ |
| Indonesia | 0 | 18 | >60 | 2 g twice a day | 21 days | 9 | 9 | Q, CT | Subjects with metabolic syndrome | HS reduced blood pressure in elderly with hypertension, lowered cortisol, and increased NO | [ |
| Egypt | NI | NI | 50 ± 5 | 8 g | 8 weeks | 50 | 50 | Q, No-R | Patients with moderate essential hypertension and the normotensive general population | Group HS with marked reductions in diastolic, systolic, and pulse pressures | [ |
| USA | 37 | 28 | 30–70 | 3.75 g | 6 weeks | 35 | 30 | R, DBT, PC | Systolic blood pressure (120–150 mm Hg) diastolic BP (<95 mm Hg), as inclusion criteria | Lowering of systolic blood pressure | [ |
| Iraq | 41 | 90 | 51 ± 10.3 (HS) | 15 g | 6 weeks | 76 | 45 | Pilot comparative intervention | Subjects without CVD, renal, or retinal complications | HS showed the presence of traces of chlorogenic acid, anthocyanins, and a large amount of hibiscus acid that could participate in the antihypertensive activity | [ |
| Capsule/Tablet | |||||||||||
| Senegal | NI | NI | 53.2 ± 14.3 | 320 mg twice daily | 28 days | 42 | 41 | P, R, C | Subjects without evidence of cardiovascular, renal, or retinal complications | Reduction in systolic blood pressure. In addition, 21% of the patients treated normalized their blood pressure vs. 39% of the control group | [ |
| Egypt | 42 | 72 | 20–60 | 1200 mg HS | 8 weeks | 39 | 39 | R, DBT, C, three-arm | The capsules provided to the subjects were based on extracts of HS and | The consumption of HS-OE reduced blood pressure to values comparable to those of captopril | [ |
| Iran | NI | NI | 18–35 | 450 mg | 6 weeks | 18 | 18 | R, DBT | Healthy adult men | Decreased systolic blood pressure with respect to the control group | [ |
| Iran | NI | NI | 47.66 ± 4.32 (HS) | 500 mg | 4 weeks | 18 | 170 | DBT, C, CT | Adults with metabolic syndrome | HS decreased systolic blood pressure and TGL with respect to control | [ |
| Beverage | |||||||||||
| Nigeria | 25 | 25 | 18–27 | 500 mL (1.4%) | The mean value of the recordings was recorded in triplicate, after 10 min in the supine position and 5 min standing | 25 | 25 | R, C, CO | Subjects with recreational activity without a regular exercise regimen | HS decreased systolic blood pressure and rate pressure product (RPP) induced by standing. | [ |
| Mexico | NI | NI | 25–61 | 250 g | 4 weeks | 86 | 84 | R, C, DBT | Subjects with hypertension stage I or II | HS significantly reduced plasma ACE activity and showed a tendency to reduce the sodium values | [ |
| Senegal | NI | NI | 20–70 | 10 g | 1, 3, 6 months | 51 (tablet) | 37 | R, C | The control group and two experimental groups were contrasted | HS in both presentations was as effective as standard treatment during a 6-month follow-up | [ |
| Nigeria | 55 | 35 | NI | 150 mg/Kg | 4 weeks | NI | NI | R | Subjects with mild to moderate hypertension | A low dose (150 mg/kg) of HS once daily reduced blood pressure hypertension | [ |
| Nigeria | NI | NI | 31–70 | 150 mg/Kg | 4 weeks | 26 (HS) | 26 | R, DBT | Mild to moderate hypertension, newly diagnosed, but not treated | HS significantly decreased systolic BP | [ |
| UK | NI | NI | 49 ± 2 | 7.5 g | 4 h | 22 | 22 | R, C, SB, CO | Improved vascular function | [ | |
| Saudi Arabia | NI | NI | NI | 1.25 g | 4 weeks | 19 | 0 | P | The sample ended with 15 subjects | No significant effects of HS use on blood pressure or lipid profile were observed | [ |
HS: Hibiscus sabdariffa; M: male; F: female; Exp: experimental group; CT: control group; O: observational; NI: no information; OxLDL: low-density lipoprotein from human plasma, oxidized; R: randomized trial; C: controlled trial; BP: blood pressure; DBT: double-blind trial; controlled trial; Q: quasi-experimental; NO: nitric oxide; PC: placebo control; CVD: cardiovascular disease; OE: Olea europaea; P: prospective trial; TGL: triglycerides; RPP: rate pressure product; ACE: angiotensin converting enzyme; CO: cross-over trial; SB: single-blind trial.
Effects of HS consumption on blood lipids.
| Country | Sex | Age (years) | Dose | Frequency/Days of Intervention | Sample Size | Design Study | Notes about Participants | Main Results | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | Exp. | CT | ||||||||
| Infusion/Decoction/Tea | |||||||||||
| Saudi Arabia | 0 | 16 | 25–35 | 2 g | 6 weeks | 16 | 0 | NI | Female participants | Lowering the OxLDL levels of participants. | [ |
| Iran | 6 | 37 | 30–60 | 2 g | 12 weeks | 21 | 22 | R, C | Adults with polygenic dyslipidemia | The intervention group showed a significant reduction in total cholesterol and LDL-c | [ |
| Iran | 35 | 37 | 14–21 | 2 g | NI | 36 | 36 | R, P, C | Adolescent population | Serum total cholesterol, LDL-c, and TGL showed a decrease in all cases | [ |
| Iran | 8 | 45 | 55.37 ± 8.6 | 2 g | 1 month | 27 | 26 | R, C | Patients with diabetes | HS decreased TGL, CT, LDL-c, and APO-B100 levels; it also increased HDL-c levels | [ |
| Iran | NI | NI | 50 ± 14 | 15 mg | 30 days | 42 | 42 | R | Patients with hypertension were treated for at least 3 months. | No significant differences were found between pre and post-experiment measurements in the groups evaluated | [ |
| Iraq | 9 | 15 | 31–65 | 15 g | 4 weeks | NI | NI | P, R, CC | Hypertension patients | The HS group showed the most significant decrease in blood pressure, cholesterol, and LDL and a decrease in urea nitrogen | [ |
| Indonesia | 0 | 18 | >60 | 2 g twice a day | 21 days | 9 | 9 | Q, CT | Subjects with metabolic syndrome | HS group reduced TC, TG, HDL, and LDL in the elderly with dyslipidemia | [ |
| Capsule/Tablet | |||||||||||
| Mexico | NI | NI | 30–71 | 100 mg | 1 month | 51 | 73 | R, P | Metabolic syndrome diagnosed according to NCEP-ATP III criteria | Hypolipidemic and hypotensive effects were reported. | [ |
| China | 16 | 26 | 18–75 | 500 mg per capsule | 4 weeks | NI | NI | R, CO | Volunteers with elevated cholesterol without supplement or medication intake | HS promoted a significant decrease in serum cholesterol levels | [ |
| China | 21 | 15 | 18–65 | 450 mg | 12 weeks | 19 | 17 | DBT, R | Obese subjects | HS capsules did not promote changes in HDL and LDL levels | [ |
| Iran | NI | NI | 47.66 ± 4.32 (HS) | 500 mg | 4 weeks | 18 | 170 | DBT, C, CT | Adults with metabolic syndrome | HS decreased systolic blood pressure and TGL with respect to control | [ |
| India | 31 | 26 | 35–60 | 1 g | 90 days | 28 | 29 | R, DBT, PC | Subjects without chronic diseases with 130–190 mg/dl serum LDL values. | The experimental group showed a 10% reduction in triglyceride values, and the placebo group showed no significant change | [ |
| Beverage | |||||||||||
| Cameroon | 32 | 0 | 25.38 ± 3.35 | 35 g | 2 weeks | 32 | 0 | NI | Subjectswere advised not to consume HS from any other source during the experimental period | Reduced the total cholesterol and LDL-c and increased HDL-c | [ |
| Indonesia | 17 | 13 | 39.33 ± 9.18 | 200 ml | 30 days | NI | NI | NI | Healthy adults | HS significantly lowered blood pressure and increased HDL | [ |
HS: Hibiscus sabdariffa; M: male; F: female; Exp: experimental group; CT: control group; NI: no information; OxLDL: low-density lipoprotein from human; R: randomized trial; C: controlled trial; TC: total cholesterol; LDL-c: low-density lipoprotein-cholesterol; P: prospective trial; TGL: triglycerides; APO-B100: apolipoprotein B-100; HDL-c: high-density lipoprotein-cholesterol; CC: clinical case-control; BP: blood pressure; Q: quasi-experimental; CO: cross-over trial; DBT: double-blind trial; PC: placebo control.
Effects of HS consumption on blood glucose levels.
| Country | Sex | Age (years) | Dose | Frequency/Days of Intervention | Sample Size | Design Study | Notes about Participants | Main Results | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | Exp. | CT | ||||||||
| Infusion/Decoction/Tea | |||||||||||
| Indonesia | NI | NI | 30–60 | 5 g | 14 days | 98 | 103 | Q | Pre-diabetic women | HS significantly decreased fasting blood glucose levels with no effect on postprandial glucose | [ |
| Indonesia | 0 | 18 | >60 | 2 g twice a day | 21 days | 9 | 9 | Q, CT | Subjects with metabolic syndrome | Postprandial glucose and cortisol levels were significantly reduced in subjects > 60 years of age | [ |
| USA | 4 | 4 | 18–43 | 10 g | 6 days | 6 | 6 | NI | One sample was collected per day for 6 days, 60 min after breakfast | HS together with a carbohydrate-rich breakfast appeared to slow the rate of increase in the glucose curve | [ |
| Capsule/Tablet | |||||||||||
| Indonesia | NI | NI | 35–65 | 1 g | 8 weeks | 30 | 30 | Exp, DBT | The control group and the HS group presented homogeneous conditions | HS 500 mg 2 times a day can significantly reduce fasting blood glucose and insulin levels | [ |
| Beverage | |||||||||||
| UK | NI | NI | 49 ± 2 | 7.5 g | 4 h | 22 | 22 | R, C, SB, CO | After 120 min of HS consumption, there was a tendency to a lower postprandial insulin response than the control group | [ | |
| Iran | 22 | 38 | 52 (mean) | 425 mg | 8 weeks | 30 | 30 | R, DBT, PC | Of the participants in the study, 80% used insulin, and 20% used glucose-lowering drugs | HS did not promote changes in fasting blood glucose levels in patients with diabetic nephropathy | [ |
| Cameroon | 32 | 0 | 25.38 ± 3.35 | 35 g | 2 weeks | 32 | 0 | NI | The preparation of the beverage granted contained sugar (180 g/L) | HS did not promote changes in blood glucose in healthy subjects aged 21 to 32 years | [ |
NI: no information; HS: Hibiscus sabdariffa; M: male; F: female; Exp: experimental group; CT: control group; Q: quasi-experimental; DBT: double-blind trial; C: controlled trial; SB: single-blind trial; CO: cross-over trial; R: randomized trial; PC: placebo control.
Effects of HS consumption on body weight.
| Country | Sex | Age (years) | Dose | Frequency/Days of Intervention | Sample Size | Design Study | Notes about Participants | Main Results | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | Exp. | CT | ||||||||
| Infusion/Decoction/Tea | |||||||||||
| Indonesia | 0 | 18 | >60 | 2 g twice a day | 21 days | 9 | 9 | Q, CT | Subjects with metabolic syndrome | HS reduced body weight vs. control group (pretest/posttest) | [ |
| Capsule/Tablet | |||||||||||
| China | 21 | 15 | 18–65 | 450 mg | 12 weeks | 19 | 17 | DBT, R | Obese subjects | HS reduced obesity and abdominal fat | [ |
| Spain | 0 | 55 | 36–69 | 250 mg | 8 weeks | 29 | 26 | R, DBT, PC | Healthy women 24–34 kg/m2 | The LC-HS groups showed a more significant decrease in body weight abdominal circumference, mainly in overweight individuals | [ |
| USA | NI | NI | 18–64 | 175 mg | 84 days | 42 | 42 | R, PC, DBT | Healthy subjects | LC-HS significantly decreased body weight | [ |
HS: Hibiscus sabdariffa; M: male; F: female; Exp: experimental group; CT: control group; Q: quasi-experimental; versus; DBT: double-blind trial; R: randomized trial; LC: Lippia citriodora; PC: placebo control; NI: no information.
Effects of HS consumption on renal function.
| Country | Sex | Age (years) | Dose | Frequency/Days of Intervention | Sample Size | Design Study | Notes about Participants | Main Results | Ref. | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | F | Exp. | CT | ||||||||
| Infusion/Decoction/Tea | |||||||||||
| Mexico | NI | NI | 30–80 | 10 g | 4 weeks | 53 | 37 | R, C, DBT | Subjects with hypertension, without drug treatment | Increased sodium excretion, a tendency for chlorine levels to decrease, no change in potassium excretion | [ |
| Iraq | 9 | 15 | 31–65 | 15 g | 4 weeks | NI | NI | P, R, CC | Hypertension patients | Decrease in BP and decrease in urea nitrogen | [ |
| Thailand | NI | NI | 36–65 | 1.5g | 15 days | 9 | 9 | NI | Healthy males | Uric acid excretion and clearance increased significantly | [ |
| Capsule/Tablet | |||||||||||
| Italy | 0 | 93 | 22–63 | 100 mg HS, | 30 days | 46 | 47 | R | Treatment combined | In the HS group, 95.7% of patients showed significant clinical improvement compared to women treated with standard antibiotic therapy | [ |
| Indonesia | 10 | 10 | 18–45 | 500 mg | 30 days | 20 | 0 | NI | Healthy volunteers | HS does not affect renal function in healthy subjects | [ |
| Beverage | |||||||||||
| Iran | 22 | 38 | 52 (mean) | 425 mg | 8 weeks | 30 | 30 | R, DBT, PC | Of the participants in the study, 80% used insulin, and 20% used glucose-lowering drugs | Reduction in blood urea nitrogen, blood creatinine, urine creatinine, and urine albumin values, as well as a significant decrease in high-sensitivity C-reactive protein | [ |
| Mexico | NI | NI | 25–61 | 250 g | 4 weeks | 86 | 84 | R, C, DBT | Subjects with hypertension stage I or II | Showed a tendency to reduce sodium, while the potassium level did not change | [ |
| Thailand | 36 | 0 | 20–30 | 16 g–24 g/day | 2 weeks | 36 | 0 | NI | Healthy subjects | Urinary excretion decreases creatinine, uric acid, citrate, tartrate, calcium, sodium, potassium, and phosphate | [ |
Exp: experimental group; SB: single-blind trial; CO: cross-over trial; O: observational; Q: quasi-experimental; HS: Hibiscus sabdariffa; M: male; F: female; CT: control group; NI: no information; R: randomized trial; C: controlled trial; DBT: double-blind trial; P: prospective trial; CC: clinical case-control; BP: blood pressure; PC: placebo control.